Suppr超能文献

经动脉化疗栓塞术重复治疗肝癌对门静脉压力影响的纵向分析

Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure.

作者信息

Frangakis Constantine, Sohn Jae Ho, Bas Ahmet, Chapiro Julius, Schernthaner Ruediger E, Lin MingDe, Hamilton James P, Pawlik Timothy M, Hong Kelvin, Duran Rafael

机构信息

Department of Biostatistics, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Baltimore, MD, United States.

出版信息

Front Oncol. 2021 Nov 5;11:639235. doi: 10.3389/fonc.2021.639235. eCollection 2021.

Abstract

OBJECTIVES

Investigate long-term effects of repeated transarterial chemoembolization (TACE) on portal venous pressure (PVP) using non-invasive surrogate markers of portal hypertension.

METHODS

Retrospective, Institutional Review Board-approved study. 99 patients [hepatocellular carcinoma (HCC) group (n=57); liver metastasis group (n=42)] who underwent 279TACEs and had longitudinal pre-/post-therapy contrast-enhanced-MRI (n=388) and complete blood work were included. Outcomes of interest were platelet count (PC), spleen volume, ascites and portosystemic collaterals. Variables included TACE type/number, tumor type, microcatheter location, Child-Pugh, baseline tumor burden (tumor number/total/largest size), vessel invasion, alpha-fetoprotein, Eastern Cooperative Oncology Group (ECOG) performance status, and Model for End-Stage Liver Disease (MELD) score. Generalized Estimating Equations assessed the associations between TACE and outcomes. Power analysis determined the sample size was sufficient.

RESULTS

No significant change in PC over time was observed in either groups, regardless of liver function (>0.05). Baseline spleen volume was 226 cm for metastatic group, and was larger by 204 cm for HCC group (<0.001). Spleen volume increased by 20 cm (95%CI: 8-32; =0.001) for both groups after 1TACE and by 16cm/TACE (=0.099) over the full follow-up (up to 9TACEs). Spleen volume also tended to increase by 23cm (95%CI: -1-48; =0.064) with higher tumor burden. Odds of developing moderate/severe ascites for metastatic patients was decreased by 0.5 (95%CI: 0.3-0.9; =0.014), regardless of the Child-Pugh, and increased by 1.5 (95%CI: 1.2-1.9; <0.001) among HCC patients with unstable Child-Pugh, whereas no change was noted with stable Child-Pugh. HCC patients with unstable Child-Pugh demonstrated a significant increase in portosystemic collaterals number over time (=0.008). PVP-related complications such as variceal bleeding post-TACE were low (0.4%).

CONCLUSION

Repeated TACEs did seem to have an impact on PVP. However, the increase in PVP had marginal effects with low portal hypertension-related complications.

摘要

目的

使用门静脉高压的非侵入性替代标志物,研究重复经动脉化疗栓塞术(TACE)对门静脉压力(PVP)的长期影响。

方法

一项经机构审查委员会批准的回顾性研究。纳入99例患者[肝细胞癌(HCC)组(n = 57);肝转移组(n = 42)],这些患者接受了279次TACE治疗,并进行了纵向治疗前/后对比增强MRI(n = 388)及全血细胞检查。感兴趣的结果指标包括血小板计数(PC)、脾脏体积、腹水和门体侧支循环。变量包括TACE类型/次数、肿瘤类型、微导管位置、Child-Pugh分级、基线肿瘤负荷(肿瘤数量/总数/最大尺寸)、血管侵犯、甲胎蛋白、东部肿瘤协作组(ECOG)体能状态及终末期肝病模型(MELD)评分。广义估计方程评估TACE与结果之间的关联。功效分析确定样本量充足。

结果

两组患者的PC均未随时间发生显著变化,无论肝功能如何(>0.05)。转移组的基线脾脏体积为226 cm,HCC组比其大204 cm(<0.001)。两组患者在接受1次TACE后脾脏体积增加20 cm(95%CI:8 - 32;=0.001),在整个随访期间(最多9次TACE)每接受1次TACE脾脏体积增加16 cm(=0.099)。肿瘤负荷较高时,脾脏体积也倾向于增加23 cm(95%CI:-1 - 48;=0.064)。无论Child-Pugh分级如何,转移患者发生中度/重度腹水的几率降低0.5(95%CI:0.3 - 0.9;=0.014),而Child-Pugh分级不稳定的HCC患者发生中度/重度腹水的几率增加1.5(95%CI:1.2 - 1.9;<0.001);Child-Pugh分级稳定的患者则无变化。Child-Pugh分级不稳定的HCC患者门体侧支循环数量随时间显著增加(=0.008)。TACE术后诸如静脉曲张出血等与PVP相关的并发症发生率较低(0.4%)。

结论

重复TACE似乎确实对PVP有影响。然而,PVP的升高影响较小,且门静脉高压相关并发症发生率较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/833a/8602787/9b1e8abc5aea/fonc-11-639235-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验